Hoth Therapeutics, Inc. (HOTH)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.4192 |
| Open | 0.4000 |
| Bid | 0.4050 x 1200 |
| Ask | 0.4200 x 3100 |
| Day's Range | 0.4000 - 0.4291 |
| 52 Week Range | 0.3800 - 1.7500 |
| Volume | |
| Avg. Volume | 4,109,470 |
| Market Cap | 13.367M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5280 |
| Earnings Date | Nov 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HOTH
Related Research
- Hoth Therapeutics, Inc.Technical Assessment: Bearish in the Intermediate-TermMonday provided a much-needed rest for the stock market after a very large rebound last week. Following that strong week (and we've seen this before during the current decline), the "bottom-callers" are out, but not in big numbers. That's probably a good thing, as others are calling this another bear-market rally. From a technical perspective and using our own interpretation, it is far too early to call the bottom as there is just not enough of the needed evidence.RatingFair ValueEconomic Moat6 days agoArgus Research
- PR Newswire
Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company") today announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market ("Nasdaq") notifying the Company that Nasdaq has granted the Company an additional 180-day compliance period, or until December 26, 2022, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement (the "Additional Compliance Period").
- PR Newswire
Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the next phase of its BioLexa trial for patients suffering with Atopic Dermatitis.
- PR Newswire
Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 (the "Annual Meeting") was adjourned until 12:00 p.m. Eastern Time on June 23, 2022 to allow additional time to solicit proxies and obtain a quorum for the Annual Meeting. No business other than the adjournment was conducted on June 15, 2022. The Annual Meeting to be held on June 23, 2022 will be held virtually at
